bioRxiv Science⌕ Search

Biology subjects

Wei, G.-W.

Publications and source records attributed to Wei, G.-W..

2 recordsLinked to original sources

Persistent spectral theory-guided protein engineering

While protein engineering, which iteratively optimizes protein fitness by screening the gigantic mutational space, is constrained by experimental capacity, various machine learning models have substantially expedited protein engineering. Three-dimensional protein structures promise further advantages, but their intricate geometric complexity hinders their applications in deep mutational screening. Persistent homology, an established algebraic topology tool for protein structural complexity reduction, fails to capture the homotopic shape evolution during the filtration of a given data. This work introduces a Topology-offered protein Fitness (TopFit) framework to complement protein sequence and structure embeddings. Equipped with an ensemble regression strategy, TopFit integrates the persistent spectral theory, a new topological Laplacian, and two auxiliary sequence embeddings to capture mutation-induced topological invariant, shape evolution, and sequence disparity in the protein fitness landscape. The performance of TopFit is assessed by 34 benchmark datasets with 128,634 variants, involving a vast variety of protein structure acquisition modalities and training set size variations.

bioinformatics↗

Revealing the threat of emerging SARS-CoV-2 mutations to antibody therapies

The ongoing massive vaccination and the development of effective intervention offer the long-awaited hope to end the global rage of the COVID-19 pandemic. However, the rapidly growing SARS-CoV-2 variants might compromise existing vaccines and monoclonal antibody (mAb) therapies. Although there are valuable experimental studies about the potential threats from emerging variants, the results are limited to a handful of mutations and Eli Lilly and Regeneron mAbs. The potential threats from frequently occurring mutations on the SARS-CoV-2 spike (S) protein receptor-binding domain (RBD) to many mAbs in clinical trials are largely unknown. We fill the gap by developing a topology-based deep learning strategy that is validated with tens of thousands of experimental data points. We analyze 261,348 genome isolates from patients to identify 514 non-degenerate RBD mutations and investigate their impacts on 16 mAbs in clinical trials. Our findings, which are highly consistent with existing experimental results about variants from the UK, South Africa, Brazil, US-California, and Mexico shed light on potential threats of 95 high-frequency mutations to mAbs not only from Eli Lilly and Regeneron but also from Celltrion and Rockefeller University that are in clinical trials. We unveil, for the first time, that high-frequency mutations R346K/S, N439K, G446V, L455F, V483F/A, E484Q/V/A/G/D, F486L, F490L/V/S, Q493L, and S494P/L might compromise some of mAbs in clinical trials. Our study gives rise to a general perspective about how mutations will affect current vaccines.

biochemistry↗